Companies/Kane Biotech Inc.

Company profile

Kane Biotech Inc.

OTC: KNBIF · Healthcare · Biotechnology

Canadian filerHQ Winnipeg, MBReports USD

#957 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

24D

FH 23DQ —GM 13SS 50

v0.1 · 45/100 weight · provisional

↑ listing tenure, disclosure history · ↓ Piotroski F, growth stability

Methodology →

Revenue TTM

$42.6k

Rev growth YoY (TTM)

-97.6%

Net income (FY)

-$1.9M

Employees

Market cap

$4.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$305.8k427.5k CAD2025

Net income-$1.9M-2.7M CAD2025

Operating income-$2.2M-3.1M CAD2025

Total assets$2.0M2.7M CAD2025

Liabilities$2.5M3.5M CAD2025

Equity-$544.2k-745.9k CAD2025

Revenue trend

FY2018 – FY2025 · USD

$390.7k

FY18

$1.3M

FY19

$1.0M

FY20

$1.3M

FY21

$2.1M

FY22

$110.4k

FY23

$1.5M

FY24

$305.8k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Kane Biotech Inc. booked $305.8k in FY2025 revenue, contracting 80% year over year — slower than 88% of Healthcare companies we track, at a -636.0% net margin.

Peers · Healthcare

Allurion Technologies Inc.27D Soligenix, Inc.42D Biotricity, Inc.——MedX Health Corp28D

Key facts

CEORobert Huizinga

SectorHealthcare

IndustryBiotechnology

HeadquartersWinnipeg, MB

ExchangeOTC: KNBIF

Employees20

IPO date2007-08-07

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.